All analyses
AI analysis

Amana Takaful PLC: research report

Moderately overvaluedneutralAug 6, 2026

Amana Takaful is freshly recapitalised after an over LKR 1 billion oversubscribed rights issue, while Q1 2026 net margin improved to 12.6%.

Reports without a focus are public, one per stock per day. Generation usually takes about 15 minutes, and we'll notify you when it's ready.

Operating margin
45.1%
of revenue plus other operating income, which is larger than revenue here
Net margin
37.9%
of revenue plus other operating income; profit here is mostly not from revenue
Return on equity
7.2%sector 7.2%
full year to Dec 31, 2025
P/E
19.5sector 13.1
earnings Rs 1.15 per share
P/B
0.99sector 1.52
book Rs 22.52 per share
Dividend yield
0.00%sector 1.78%
trailing twelve months

Current figures, updated daily from filings to Jun 30, 2026. The report below was written on Aug 6, 2026. Sector figures are the median of 11 listed companies in the same sector.

Overview

Amana Takaful is a Shariah-compliant multi-line insurer spanning family (life) and general takaful, distributing via branches, agents, bancassurance and digital channels. The company is now better capitalised after a rights issue raising over LKR 1 billion to support growth, digital upgrades and SLFRS 17/9 readiness. At a market capitalisation of LKR 5.99 billion, the key near-term swing factor is execution: sustaining the operational improvement shown in the March 2026 quarter while deploying new capital without eroding returns. As a takaful operator, earnings are leveraged to underwriting discipline and investment returns, with regulatory transition set to reshape reporting and product economics. The investment case balances improved profitability momentum with the realities of post-raise dilution and a still-moderate return profile.

Price performance

The share has de-rated over the medium term, falling 20.4% over six months, but remains up 23.6% over one year. It trades within a wide 52-week range of LKR 14.54 to LKR 30.45, indicative of shifting expectations as capital and earnings reset. Trading liquidity is modest and the stock’s beta to the ASPI is high at 1.95, meaning moves are often amplified relative to the index. Note that an April rights issue increased the share count; headline returns shown here are restated to today’s basis, while as-traded screens will differ. That divergence reflects the corporate action rather than a change in underlying performance.

Valuation

ATL screens inexpensive versus insurance peers on earnings, at a P/E of 10.9 against a sector median of 14.8. It also trades around book at a P/B of 1.0. The discount is largely explained by a modest ROE of 7.2 that trails the sector’s returns, and by the absence of an income component: the dividend yield is 0.0 versus a sector median of 7.5. In short, investors are paying close to book for a business that is still rebuilding profitability and capital strength. A sustained uplift in returns should warrant re-rating; without it, the current multiples appear fair for the risk.

News and sentiment

Coverage has been steady, with six material articles in the last 90 days: two positive and four neutral. The most important development is the completion of the rights issue, which raised over LKR 1 billion and was 68.8% oversubscribed, signalling shareholder support for the growth and regulatory-readiness agenda. Corporate disclosures also noted board changes, including an independent director stepping down, and a Takeovers Code Section 36 disclosure. Confirmed corporate actions show the April 17, 2026 rights ex-date. Overall sentiment is constructive but cautious, consistent with a capital-backed plan that now needs operating delivery.

Financials

Momentum improved in the March 2026 quarter. Revenue was LKR 3.54 billion, with operating margin at 14.1% versus 10.2% a year earlier, and net margin at 12.6% versus 7.9%. The below-the-line drag was contained, with finance, tax and other items reducing profit by LKR 55.9 million. Gross margin is not disclosed in this format for insurers. Note that per-share comparisons across 2025 are affected by share-count changes, and the April-June 2026 rights issue occurred after the reported quarter, so further dilution will appear in subsequent periods. The picture is one of improving core profitability exiting 2025, but from a still-moderate base and with capital now higher ahead of SLFRS 17 implementation.

Risks

Key risks centre on execution and sensitivity to markets. A highly index-sensitive share price can amplify market swings, which, together with modest trading liquidity at times, can sharpen drawdowns. Post-raise dilution elevates the bar for per-share earnings delivery, while the transition to SLFRS 17/9 may reshape reported profit timing and capital metrics. Insurance earnings also hinge on underwriting discipline and reinvestment yields; shifts in rates or the rupee can move investment income and reinsurance costs. The absence of a dividend removes a valuation backstop if growth stalls. Governance changes require attention to continuity in risk and capital management.

Outlook

With capital raised, the next proof points are operational. Watch for sustained double-digit net margins and evidence that investment income holds up as assets are redeployed at prevailing yields. Post-rights share issuance makes per-share earnings and book value accretion the litmus tests; early signs should emerge in the June and September quarters. Clarity on SLFRS 17 impacts and any recalibration of product pricing or reserves will also be important. If underwriting strengthens and returns trend higher from the current single digits, valuation has room to normalise toward sector levels; if margins slip or capital sits idle, the discount is likely to persist.

About this report. Generated on Aug 6, 2026 from market data up to Aug 5, 2026, 6 material news articles over 90 days and financials to Mar 31, 2026. Every figure is drawn from EquityLK's own data on this company. AI research can contain errors, so treat it as a starting point, not investment advice.

Previous reports